Clinical trial • Phase II • Other
Canagliflozin for Healthy volunteers
Phase II trial of Canagliflozin for Healthy volunteers. 36 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 10-04-2026
- First CTIS Authorization Date
- 29-04-2026
Trial design
Phase II trial in Spain.
- Target Sample Size
- 36
Eligibility
Recruits 36 isVulnerablePopulationSelected: true; no further details on vulnerable population handling, consent or assent available in the provided source..
- Vulnerable Population
- isVulnerablePopulationSelected: true; no further details on vulnerable population handling, consent or assent available in the provided source.
Recruitment
- Planned Sample Size
- 36
- Recruitment Window Months
- 1
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 36
Spain
- Earliest CTIS Part Ii Submission Date
- 26-02-2026
- Latest Decision Or Authorization Date
- 29-04-2026
- Processing Time Days
- 62
- Number Of Sites
- 1
- Number Of Participants
- 36
Sites
- Site Name
- Hospital Universitario De La Princesa
- Department Name
- Clinical Pharmacology Department
- Contact Person Name
- Dolores Ochoa
- Contact Person Email
- mdolores.ochoa@salud.madrid.org
Sponsor
Primary sponsor
- Full Name
- Laboratorios Normon S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- Canagliflozin (two formulations)
- Active Substance
- Canagliflozin
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
Related trials
Other published trials that may interest you.